Compounds inhibiting Cox-2 are of special interest for antiangiogenic therapy because prostaglandins mediated by Cox-2 have been shown to be important contributors to VEGF dependent tumor angiogenesis [27]. This evidence concerns the gene VEGFA and neoplasm.